Acrivon Therapeutics, Inc.: Promising Advancements and Strong Buy Rating Backed by Innovative Pipeline and Solid Financial Position
TD Cowen analyst Marc Frahm has maintained their bullish stance on ACRV stock, giving a Buy rating today. Marc Frahm has given his Buy rating ...